Kidney transplant drug boosts immune activity in breast cancer

Share this article:

The immunosuppressant agent daclizumab, which is used to prevent acute organ rejection in persons undergoing renal transplants, has now been shown to improve survival by 30% in patients with breast cancer who received a therapeutic vaccine.

Robert H. Vonderheide, MD, DPhil, and James Riley, PhD, both of the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, led a team that theorized daclizumab could effectively deplete regulatory T cells (Tregs) and restore the immune system's ability to fight tumors. As the investigators wrote in Science Translational Medicine (2012;4[134]:134ra62), Tregs are key mediators of immune tolerance and feature prominently in cancer. Tumor cells draw Tregs to the tumor area, where the Tregs rely on the protein IL-2 for most of their functions.

Daclizumab is a monoclonal antibody that binds to the CD25 receptor on the surfaces of Tregs, depriving the cells of IL-2. The lack of IL-2 forces Tregs to convert into normal T cells that no longer surround the tumor, allowing immune cells to make their way in to battle the tumor.

To learn more about the impact of daclizumab on Tregs in humans, Vonderheide, Riley, and colleagues performed a clinical trial of daclizumab in combination with an experimental cancer vaccine being developed at their facility. Among the 10 study participants, all of whom had metastatic breast cancer, the agent worked “incredibly well,” said Vonderheide in an announcement from the medical school: The T-cell conversion lasted 2 months and no side effects were detected. Although the tumors did not shrink, they did stop growing in six of the patients. The patients receiving the vaccine plus daclizumab survived about 7 months longer than those given vaccine only.

Because Tregs can block the immune response against most human cancers, “Drugs like daclizumab might be useful for most cancer patients, especially those receiving other types of immune therapy,” noted Vonderheide.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Support team aids decision-making by caregivers of terminal cancer patients

Researchers devised an intervention that quickly integrates a cancer support team to guide caregivers and their patients through difficult end-of-life treatment and decisions.

Protein inhibition opens door for pancreatic cancer treatment

The protein galectin-1 has been identified as a possible therapeutic target for pancreatic cancer; new research has demonstrated that inhibiting this protein in mice with pancreatic cancer increased survival by 20%.

Noninvasive advanced image analysis may improve care for lung cancer patients

Lung cancer patients could receive more precise treatment, and their progress could be better tracked by using a new high-tech method of non-invasive medical imaging analysis, according to a new study.